Eikon Therapeutics Inc. Common Stock

EIKN | NASDAQ

$5.31

-$0.04 (-0.75%)

At close: Oct 30, 2026, 4:00 PM ET

$5.49

+$0.18 (+3.39%)

Pre-market: Nov 2, 2026, 4:00 AM ET

Fiscal Quarter Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025
Revenue	n/a	n/a	n/a	n/a
Cost of Revenue	5.03M	5.11M	5.11M	n/a
Gross Profit	-5.03M	-5.11M	-5.11M	n/a
Operating Income	-93.39M	-87.34M	-83.17M	-74.75M
Interest Income	5.04M	4.38M	3.47M	n/a
Pretax Income	-88.41M	-82.96M	-79.66M	-71.14M
Net Income	-88.41M	-82.96M	-79.66M	-71.14M
Selling & General & Admin	12.91M	12.18M	17.94M	15.44M
Research & Development	75.46M	70.05M	65.23M	59.31M
Other Expenses	n/a	n/a	-5.11M	n/a
Operating Expenses	88.37M	82.22M	78.06M	74.75M
Interest Expense	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a
Cost & Expenses	93.39M	87.34M	83.17M	74.75M
Income Tax Expense	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	54.15M	54.14M	54.14M	n/a
Shares Outstanding (Diluted)	54.15M	54.14M	54.14M	n/a
EPS (Basic)	-1.63	-1.53	-1.47	n/a
EPS (Diluted)	-1.63	-1.53	-1.47	n/a
EBITDA	-88.37M	-77.85M	-74.55M	-56.39M
EBIT	-93.39M	-82.96M	-79.66M	-62.68M
Depreciation & Amortization	5.03M	5.11M	5.11M	6.3M